Data May Provide “Framework” for Mitigating Cancer Surgery Disparities

Commentary
Video

Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.

Data from a retrospective analysis indicated how residential segregation may contribute to inequalities in cancer mortality for patients who undergo surgery, which may provide a “framework” for future policies designed to mitigate these disparities, said Muhammad Talha Waheed, MD.

Waheed, a research fellow in the Department of Surgical Oncology at City of Hope National Medical Center in Duarte, California, spoke with CancerNetwork® about findings presented at the 2024 Society of Surgical Oncology Annual Meeting (SSO) from a study assessing the impact of racial/economic segregation on patient-level accessibility, timeliness, and appropriateness of treatment for cancer.

Although Waheed stated that the presentation highlighted inequities in access to care and mortality across different demographics, he acknowledged that exploring the mechanisms that drive these disparities is another question that must be addressed. Additionally, he said that he would share the results of his study with policymakers in California to help inspire legislature that may improve treatment access and quality for patients in disadvantaged areas.

Transcript:

This study highlights the issues that are on the systemic level and brings forward the impact of very longstanding racist policies. It’ll be hard to do anything each year to address these issues. The study shows the zip codes, areas, and disease sites that are being affected the most, and it sheds [light] on the mechanism that is driving these disparate survivals. That was the biggest question. It’s easier to find this disparate access and mortality, but what are the mechanisms that are driving these differences?

These are important points that we need to focus on. It provides the framework for state- and federal-level policies to prioritize and target these areas, the disease sites, accessibility, and timeliness appropriateness of cancer treatment. These patients residing in disadvantaged areas should have equal access and quality of cancer care. We will share these findings with stakeholders and policymakers in California. They can maybe use this as a guiding principle and make some policies.

Reference

Waheed MT, Sullivan KM, Haye S, et al. Impact of racialized residential segregation on guideline concordant cancer care and survival. Presented at the Society of Surgical Oncology (SSO) 2024 Annual Meeting; March 20 – 23, 2024; Atlanta, GA; abstract E126.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content